Dilated cardiomyopathy with hypergonadotropic hypogonadism

From WikiMD's WELLNESSPEDIA

Other Names: Cardiogenital syndrome; Najjar syndrome; Malouf syndrome; Genital anomaly with cardiomyopathy; Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome Dilated cardiomyopathy with hypergonadotropic hypogonadism (DCMHH) is a condition that primarily affects the heart and gonads (male testes or female ovaries).

Cause[edit]

Some cases of DCMHH are caused by mutations in the LMNA gene.

Inheritance[edit]

Both autosomal dominant and autosomal recessive inheritance patterns have been described.

Signs and symptoms[edit]

It is characterized by a disease of the heart muscle (dilated cardiomyopathy) and little or no production of sex hormones due to a problem with the pituitary gland or hypothalamus (hypergonadotropic hypogonadism). Other symptoms might include: characteristic facial features, intellectual disability, mild skeletal anomalies, and abnormalities of the metabolic system.

For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. 80%-99% of people have these symptoms

5%-29% of people have these symptoms

Diagnosis[edit]

There are no established diagnostic criteria for DCMHH. The diagnosis is made based on findings of characteristic signs and symptoms. The diagnosis might be confirmed with genetic testing, including analysis of the LMNA gene.

Treatment[edit]

Although there is no specific treatment or cure for DCMHH, there are ways to manage the symptoms. A team of doctors or specialists is often needed to figure out the treatment options for each person.


NIH genetic and rare disease info[edit]

Dilated cardiomyopathy with hypergonadotropic hypogonadism is a rare disease.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.